secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001558370-23-015582
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus completes acquisition of Surface Oncology for ~$66.9M in stock and CVRs
-------------------------------------------------------------------------------

- Coherus issued 0.1960 shares per Surface share for total consideration of ~$66.9M ($40M + 26.9M net cash).
- Surface shareholders received CVRs for 70% of milestone/royalty value from Novartis and GSK programs, and 25-50% of future ex-US licensing payments for CHS-114 and casdozokitug.
- Acquired pipeline: toripalimab (anti-PD-1 under BLA review), casdozokitug (IL-27 antibody Phase 2), CHS-114 (CCR8 antibody Phase 1/2), CHS-006 (TIGIT antibody Phase 1/2).
- Surface common stock delisted from Nasdaq Capital Market effective September 8, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023015582/0001558370-23-015582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837023015582/chrs-20230908x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer